Precision therapeutics for fibrotic disease
Our Science
At Forth Therapeutics, we're pioneering precision therapeutics that target the underlying mechanisms driving fibrosis. Building on world-renowned research from Professor Neil Henderson at the University of Edinburgh, we leverage multi-omic insights from patient-derived tissue samples to develop potent, new therapies for patients.
Novel Approach to Fibrotic Disease
We combine cutting-edge single cell and spatial genomics approaches to identify antifibrotic targets with high precision. By focusing on specific markers of pathogenic cells, we're able to develop targeted interventions to halt and potentially reverse the course of fibrotic disease.
Unparalleled data access
Our platform combines high-resolution mapping of the fibrotic niche with one of the largest single-cell human liver disease datasets in the world. Using advanced computational models and machine learning algorithms, we integrate data from multiple single cell and spatial genomics platforms to create a high-definition map of fibrotic disease, thereby accelerating precision drug discovery and development.
Our Therapies
Our portfolio includes three assets targeting key fibrosis pathways, underpinned by state-of-the-art omics technology. We believe our technology has broad applicability across fibrotic diseases. We will be announcing further details for our therapeutic development pipeline in Q4 2025.
Leadership
Alex Leech MBA
Chief Executive Officer
Neil Henderson MD PhD FMedSci
Chief Scientific Officer
Ralph Minter PhD
Chief Technology Officer
Careers
Loading opportunities...
Contact Us
Have questions about our work or want to discuss potential partnerships? Please get in touch.